

# Erratum: Quebec Platelet Disorder: Update on Pathogenesis, Diagnosis, and Treatment

Catherine P.M. Hayward, MD, PhD, FRCP(C)<sup>1</sup> Georges E. Rivard, MD, FRCP(C), FAAP<sup>2</sup>

<sup>1</sup>Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada

<sup>2</sup>Service d'Hématologie-Oncologie, CHU Sainte-Justine, Montréal, Québec, Canada

Address for correspondence Catherine P.M. Hayward, MD, PhD, FRCP(C), Department of Pathology and Molecular Medicine, McMaster University, 2N29A, 1200 Main St. W., Hamilton, Ontario, L8N 3Z5, Canada (e-mail: haywrdc@mcmaster.ca).

Semin Thromb Hemost 2019;45:121–122.

## ERRATUM

The publisher has been informed that there were errors in ►**Table 1** in the above article in *Seminars in Thrombosis and Hemostasis*, Volume 37, Number 6, 2011 (DOI: 10.1055/s-0031-1291382).

The plasma thrombopoietin (TPO) values and TPO assay reference interval that the authors were provided were incorrect. They apologize for not catching these errors before publication. Plasma TPO levels (determined with new samples and the same assay) are actually <31.3 pg/ml in QPD and most general population control samples.<sup>1</sup> A new version of ►**Table 1**, with the correct information,<sup>1</sup> is included in this erratum. No other information in the authors' review requires correction.

**Table 1** Laboratory findings in Quebec platelet disorder

Laboratory test	Finding
Platelet count	Reduced or normal ( $80\text{--}245 \times 10^9/\text{L}$ )
Other blood counts	Normal unless iron deficient
Platelet Function Analyzer-100® closure times	Normal
Bleeding time	Normal to mildly prolonged
<i>Coagulation and fibrinolysis parameters</i>	
PT (INR)	Normal
aPTT	Normal
Fibrinogen	Normal
D-dimer	Normal
uPA	Normal in plasma prepared with platelet activation inhibitors Elevated in platelets ( $\sim 400\text{--}600 \text{ ng uPA}/10^9 \text{ platelets}$ )
uPA-plasminogen activator inhibitor 1 complexes	Normal in plasma Elevated in platelets
Plasmin- $\alpha 2$ plasmin inhibitor complexes	Normal in plasma Elevated in platelets
Thromboelastography (whole blood or platelet rich plasma)	Normal
<i>Light transmission platelet aggregometry</i>	Non-diagnostic findings
Epinephrine	Absent primary or absent secondary aggregation
Adenosine diphosphate	Normal to reduced
Collagen	Normal to reduced
Arachidonic acid	Normal
Thromboxane analogue U46619	Normal
Ristocetin	Normal
<i>Platelet glycoprotein analysis</i>	
Western blot analysis for $\alpha$ -granule protein degradation and platelet uPA	$\alpha$ -granule protein degradation and increased platelet uPA
Plasma thrombopoietin levels	$<31.3 \text{ pg/mL}$ (reference interval: $<31.3 \text{ pg/mL} - 196 \text{ pg/mL}$ )
Genetic tests for the QPD <i>PLAU</i> duplication mutation	Positive (duplicated and normal alleles detected)

Abbreviations: ADP, adenosine diphosphate; aPTT, activated partial thromboplastin time; PT (INR), prothrombin time (international normalized ratio); QPD, Quebec platelet disorder; uPA, urokinase plasminogen activator.

Note: The only correction in this table, as compared with the previous version, relates to plasma thrombopoietin levels. All other information is as per previously published. The entire table is provided here for completeness and ease of referral.

### References

- 1 Hayward CP, Tasneem S, Rivard GE. Thrombopoietin levels in Quebec platelet disorder: Implications for the mechanism of thrombocytopenia. *Int J Lab Hematol* 2018. Doi: 10.1111/ijlh.12781